BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
latest_posts
- 1
Hilary Duff's husband responds to Ashley Tisdale's 'toxic' mom group claims: The drama, explained - 2Dolly Parton misses Dollywood event due to 'a few health challenges' after skipping honorary Oscars
- 3Instructions to Grasp the Innovation Behind 5G Pinnacles\
- 4This Miraculous, Cliff-Perched Town In The South Of France Is A Sacred European Gem
- 5Greece eyes migrant repatriation centres outside the EU
- 'Wicked: For Good' was filmed at this surreal National Park in Egypt
- Giude to Best Web based Learning Stage
- 2 of Earth's rarest lightning phenomena captured simultaneously in once-in-a-lifetime photo
- Vote In favor of Your Number one Savvy Beds
- What are parents to do as doctors clash with Trump administration over vaccines?
- AstraZeneca to invest $2 billion as part of US manufacturing push
- The Force of Care: Living with Goal
- Iran slams UN nuclear watchdog for failing to condemn Bushehr attacks
- Politics at the table? Drinking the wine you brought? An etiquette expert's Thanksgiving dos and don'ts.
